In our cohort, HER2 expression by CNV, mRNA, and IHC was negligible in cancers of nonepithelial origin, including bone sarcomas, soft tissue sarcomas, kidney, melanoma, neuroendocrine tumors, and small-cell lung cancers. Here, ERBB2 is linked to bone sarcoma.